NUVB vs. ALLO

Last updated Jun 4, 2026

NUVB (Nuvation Bio Inc.) and ALLO (Allogene Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, NUVB returned -17.37%/yr vs -39.07%/yr for ALLO. At a 0.39 correlation, their price movements are largely independent.

Performance

NUVB vs. ALLO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nuvation Bio Inc. (NUVB) and Allogene Therapeutics, Inc. (ALLO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, NUVB achieves a -47.32% return, which is significantly lower than ALLO's 45.99% return.

NUVB

• 1D: -3.67%
• 1M: 7.03%
• YTD: -47.32%
• 6M: -43.61%
• 1Y: 92.65%
• 3Y*: 40.28%
• 5Y*: -17.37%
• 10Y*: —

ALLO

• 1D: -2.44%
• 1M: -11.50%
• YTD: 45.99%
• 6M: 31.58%
• 1Y: 48.15%
• 3Y*: -29.09%
• 5Y*: -39.07%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

NUVB vs. ALLO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
NUVB Nuvation Bio Inc.	-47.32%	236.84%	76.16%	-21.35%	-77.41%	-27.35%	17.00%
ALLO Allogene Therapeutics, Inc.	45.99%	-35.68%	-33.64%	-48.97%	-57.84%	-40.89%	-27.24%

Correlation

The correlation between NUVB and ALLO is 0.38, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.38
Correlation (3Y) Calculated over the trailing 3-year period	0.41
Correlation (5Y) Calculated over the trailing 5-year period	0.43
Correlation (All Time) Calculated using the full available price history since Aug 25, 2020	0.39

Fundamentals

Market Cap NUVB : $1.78B ALLO : $480.58M
EPS NUVB : -$0.42 ALLO : -$0.77
PB Ratio NUVB : 5.58 ALLO : 1.72
Total Revenue (TTM) NUVB : $143.05M ALLO : $0.00
Gross Profit (TTM) NUVB : $131.08M ALLO : -$34.22M
EBITDA (TTM) NUVB : -$139.03M ALLO : -$170.97M

Return for Risk

NUVB vs. ALLO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NUVB

NUVB Risk / Return Rank: 71
NUVB Sharpe Ratio Rank: 72
NUVB Sortino Ratio Rank: 74
NUVB Omega Ratio Rank: 75
NUVB Calmar Ratio Rank: 70
NUVB Martin Ratio Rank: 65

ALLO

ALLO Risk / Return Rank: 62
ALLO Sharpe Ratio Rank: 60
ALLO Sortino Ratio Rank: 62
ALLO Omega Ratio Rank: 60
ALLO Calmar Ratio Rank: 66
ALLO Martin Ratio Rank: 61

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NUVB vs. ALLO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nuvation Bio Inc. (NUVB) and Allogene Therapeutics, Inc. (ALLO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NUVB	ALLO	Difference
Sharpe ratio Return per unit of total volatility	1.02	0.56	+0.46
Sortino ratio Return per unit of downside risk	1.95	1.36	+0.59
Omega ratio Gain probability vs. loss probability	1.27	1.17	+0.10
Calmar ratio Return relative to maximum drawdown	1.62	1.27	+0.35
Martin ratio Return relative to average drawdown	2.97	2.22	+0.75
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NUVB vs. ALLO - Sharpe Ratio Comparison

The current NUVB Sharpe Ratio is 1.02, which is higher than the ALLO Sharpe Ratio of 0.56. The chart below compares the historical Sharpe Ratios of NUVB and ALLO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	NUVB	ALLO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.02	0.56	+0.46
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.23	-0.46	+0.23
Sharpe Ratio (All Time) Calculated using the full available price history	-0.17	-0.36	+0.19

Drawdowns

NUVB vs. ALLO - Drawdown Comparison

The maximum NUVB drawdown since its inception was -93.39%, roughly equal to the maximum ALLO drawdown of -98.24%. Use the drawdown chart below to compare losses from any high point for NUVB and ALLO.

Drawdown Indicators

	NUVB	ALLO	Difference
Max Drawdown Largest peak-to-trough decline	-93.39%	-98.24%	+4.85%
Max Drawdown (1Y) Largest decline over 1 year	-57.55%	-38.24%	-19.31%
Max Drawdown (3Y) Largest decline over 3 years	-58.19%	-84.01%	+25.82%
Max Drawdown (5Y) Largest decline over 5 years	-92.88%	-96.55%	+3.67%
Current Drawdown Current decline from peak	-67.60%	-96.30%	+28.70%
Average Drawdown Average peak-to-trough decline	-65.50%	-65.84%	+0.34%
Ulcer Index Depth and duration of drawdowns from previous peaks	31.33%	21.75%	+9.58%

Volatility

NUVB vs. ALLO - Volatility Comparison

Nuvation Bio Inc. (NUVB) and Allogene Therapeutics, Inc. (ALLO) have volatilities of 18.34% and 18.17%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NUVB	ALLO	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.34%	18.17%	+0.17%
Volatility (6M) Calculated over the trailing 6-month period	52.92%	70.81%	-17.89%
Volatility (1Y) Calculated over the trailing 1-year period	91.39%	86.95%	+4.44%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	75.57%	85.50%	-9.93%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	73.03%	77.99%	-4.96%

Dividends

NUVB vs. ALLO - Dividend Comparison

Neither NUVB nor ALLO has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both NUVB and ALLO in my portfolio?

NUVB and ALLO have a correlation of 0.38, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, NUVB or ALLO?

NUVB has higher volatility (18.34%) compared to ALLO (18.17%). In terms of maximum drawdown, NUVB dropped -93.39% vs ALLO's -98.24%.

Which has better risk-adjusted returns?

NUVB currently has the higher Sharpe Ratio (1.02 vs 0.56), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.